Association between serum total antioxidant status and flow-mediated dilation in patients with systemic lupus erythematosus: An observational study

Anadolu Kardiyoloji Dergisi

Volumn 15, Issue 11, 2015, Pages 913-918

  Sincer, İsa ^a   Kurtoğlu, Ertuğrul ^b   Çoşkun, Fatma Yılmaz ^a   Aktürk, Semra ^c   Vuruşkan, Ertan ^a   Düzen, İrfan Veysel ^d   Saraçoğlu, Erhan ^a   Aktürk, Erdal ^e   Hidayet, Şıho ^b  

^a Dr Ersin Arslan State Hospital   (Turkey)

^b MALATYA STATE HOSPITAL   (Turkey)

^c Adiyaman Devlet Hastanesi   (Turkey)

^d Gaziantep 25 Aralik Hospital   (Turkey)

^e ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Endothelial dysfunction; Flow mediated dilation; High sensitivity C reactive protein; Systemic lupus erythematosus; Total antioxidant status

Indexed keywords

C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; 2,2' AZINOBIS(3 ETHYLBENZOTHIAZOLINE 6 SULFONIC ACID); ANTIOXIDANT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METMYOGLOBIN; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; HEART LEFT VENTRICLE FAILURE; HUMAN; MALE; OBSERVATIONAL STUDY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VASODILATATION; VEIN PUNCTURE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; HEART RATE; HYPEREMIA; INFLAMMATION; LIPID PEROXIDATION; OXIDATIVE STRESS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; ANTIOXIDANTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 84947059652     PISSN: 13028723     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2015.5764     Document Type: Article

References (30)

1. Lerang K, Gilboe IM, Steinar Thelle D, Gran JT. Mortality and years of potential life loss in systemic lupus erythematosus: A population- based cohort study. Lupus 2014; 23: 1546-52. [CrossRef]
2. Baharfard N, Shiroodi MK, Fotoohi F, Samangooie S, Asli IN, Eghtesadi-Araghi P, et al. Myocardial perfusion imaging using a technetium-99m sestamibi in asymptomatic and low risk for coronary artery disease patients with diagnosed systemic lupus erythematosus. Perfusion 2011; 26: 151-7. [CrossRef]
3. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406. [CrossRef]
4. Zeller CB, Appenzeller S. Cardiovascular disease in systemic lupus erythematosus: The role of traditional and lupus related risk factors. Curr Cardiol Rev 2008; 4: 116-22. [CrossRef]
5. Knight JS, Kaplan MJ. Cardiovascular disease in lupus: Insights and updates. Curr Opin Rheumatol 2013; 25: 597-605. [CrossRef]
6. Matsuzawa Y, Lerman A. Endothelial dysfunction and coronary artery disease: Assessment, prognosis, and treatment. Coron Artery Dis 2014; 25: 713-24. [CrossRef]
7. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73 :411-8. [CrossRef]
8. Chin CW, Chin CY, Ng MX, Le TT, Huang FQ, Fong KY, et al. Endothelial function is associated with myocardial diastolic function in women with systemic lupus erythematosus. Rheumatol Int 2014; 34: 1281-5. [CrossRef]
9. Zardi EM, Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus. Are they early markers of subclinical atherosclerosis? Autoimmun Rev 2010; 9: 684-6. [CrossRef]
10. Koca SS, Karaca I, Yavuzkır MF, Dağlı N, Özgen M, Üstündağ B, et al. Insulin resistance is related with oxidative stress in systemic lupus erythematosus. Anatol J Cardiol 2009; 9: 23-8.
11. Tam LS, Li EK, Leung VY, Griffith JF, Benzie IF, Lim PL, et al. Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: A double blind, placebo controlled pilot study. J Rheumatol 2005; 32: 275-82.
12. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86. [CrossRef]
13. Korkmaz H, Önalan O. Evaluation of endothelial dysfunction: Flowmediated dilation. Endothelium 2008; 15: 157-63. [CrossRef]
14. Wade NS, Major AS. The problem of accelerated atherosclerosis in systemic lupus erythematosus: Insights into complex co-morbidity. Thromb Haemost 2011; 106: 849-57. [CrossRef]
15. Hassan SZ, Gheita TA, Kenawy SA, Fahim AT, El-Sorougy IM, Abdou MS. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: Relationship to disease manifestations and activity. Int J Rheum Dis 2011; 14: 325-31. [CrossRef]
16. Schulze PC, Lee RT. Oxidative stress and atherosclerosis. Curr Atheroscler Rep 2005; 7: 242-8. [CrossRef]
17. Shah D, Kiran R, Wanchu A, Bhatnagar A. Oxidative stress in systemic lupus erythematosus: Relationship to Th1 cytokine and disease activity. Immunol Lett 2010; 129: 7-12. [CrossRef]
18. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: Correlation with disease activity. Arthritis Rheum 2010; 62: 2064-72.
19. Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-94. [CrossRef]
20. Yılmaz S, Çalışkan M, Kulaksızoğlu S, Çiftçi O, Çalışkan Z, Güllü H, et al. Association between serum total antioxidant status and coronary microvascular functions in patients with SLE. Echocardiography 2012; 29: 1218-23. [CrossRef]
21. Wang DG, Tang XW, Fan Y, Leng RX, Ni J, Deng SM, et al. Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: A meta-analysis. Inflammation 2014; 37: 2067-75. [CrossRef]
22. Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: A systematic review with metaanalysis. Int J Cardiol 2013; 168: 344-51. [CrossRef]
23. El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, et al. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404. [CrossRef]
24. Piper MK, Raza K, Nuttall SL, Stevens R, Toescu V, Heaton S, et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 2007; 16: 84-8. [CrossRef]
25. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59: 1814-20. [CrossRef]
26. Yılmaz Y, Öngen Z. The importance of non-lipid risk factors: A review focusing on C-reactive protein. Turk Kardiyol Dern Ars 2009; 37: 7-13.
27. Barnes EV, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: Relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576-82. [CrossRef]
28. Amaya-Amaya J, Rojas-Villarraga A, Anaya JM. Cardiovascular disease in the antiphospholipid syndrome. Lupus 2014; 23: 1288-91. [CrossRef]
29. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38. [CrossRef]
30. Karadağ O, Calgüneri M, Atalar E, Yavuz B, Akdoğan A, Kalyoncu U, et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol 2007; 26: 695-9. [CrossRef]